Ascentage Pharma Group International (AAPG) Other Non-Current Liabilities (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $1.7 million as the latest value for Q4 2025.
- For Q4 2025, Other Non-Current Liabilities rose 94.21% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, up 94.21%, while the annual FY2025 figure was $1.7 million, 100.0% up from the prior year.
- Other Non-Current Liabilities hit $1.7 million in Q4 2025 for Ascentage Pharma Group International, up from $873439.4 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.5 million in Q4 2023 and bottomed at $873439.4 in Q4 2024.
- Average Other Non-Current Liabilities over 3 years is $1.7 million, with a median of $1.7 million recorded in 2025.
- Year-over-year, Other Non-Current Liabilities plummeted 65.63% in 2024 and then skyrocketed 94.21% in 2025.
- Ascentage Pharma Group International's Other Non-Current Liabilities stood at $2.5 million in 2023, then tumbled by 65.63% to $873439.4 in 2024, then surged by 94.21% to $1.7 million in 2025.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.7 million, $873439.4, and $2.5 million for Q4 2025, Q4 2024, and Q4 2023 respectively.